Biological disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts.

Burkhard MöllerGodehard A ScholzJennifer AmslerAdrian CiureaRaphael MicheroliMichael J NissenEleftherios PapagiannoulisChristoph BlappAlmut SchererNikhil Yawalkarnull null

Published in: Rheumatology (Oxford, England) (2023)

Biological DMARDs were similarly effective in terms of drug retention in patients with low and high joint counts. In the setting of absent remission and a significant disease burden, bDMARDs should not be withheld from patients because they exhibit only a low joint count.

Keyphrases

peripheral blood
end stage renal disease
ejection fraction
rheumatoid arthritis
risk factors
disease activity
systemic lupus erythematosus
rheumatoid arthritis patients
patient reported